Patient, disease, and transplantation characteristics
| Clinical characteristics . | All patients, N = 84 . | “Low” BMI-1 group, n = 42 . | “High” BMI-1 group, n = 42 . | P* . |
|---|---|---|---|---|
| Median age, y (range) | 36.0 (4.9-59.1) | 36.3 (4.9-59.1) | 33.4 (9.7-55.4) | .91 |
| Patient/donor sex, no. (%) | ||||
| Male/male | 23 (27) | 12 (29) | 11 (26) | |
| Male/female | 25 (30) | 17 (40) | 8 (19) | .76 |
| Female/male | 13 (16) | 6 (14) | 7 (17) | |
| Female/female | 23 (27) | 7 (14) | 16 (38) | |
| Patient/donor CMV serologic status, no. (%) | ||||
| Negative/negative | 21 (25) | 7 (17) | 14 (33) | |
| Negative/positive | 24 (29) | 14 (33) | 10 (24) | .3 |
| Positive/negative | 5 (6) | 2 (5) | 3 (7) | |
| Positive/negative | 34 (40) | 19 (45) | 15 (36) | |
| Allo-SCT era, no. (%) | ||||
| Prior to 1994 | 50 | 25 (59) | 17 (41) | .08 |
| 1994-2002 | 50 | 17 (41) | 25 (59) | |
| Conditioning regimen prior to allo-SCT | ||||
| High-dose chemotherapy alone | 5 (6) | 4 (10) | 1 (2) | |
| Chemotherapy and 10 Gy TBI | 10 (12) | 5 (12) | 5 (12) | .11 |
| Chemotherapy and 12 Gy TBI | 29 (35) | 18 (43) | 11 (26) | |
| Chemotherapy and 13.2 Gy TBI | 40 (47) | 15 (36) | 25 (60) | |
| GVHD prophylaxis regimen, no. (%) | ||||
| Cyclosporine A and methotrexate | 68 (81) | 32 (76) | 36 (86) | .27 |
| T-cell depletion | 16 (19) | 10 (24) | 6 (14) | |
| EBMT-Gratwohl score, no. (%) | ||||
| 1-2 | 27 (32) | 12 (29) | 15 (36) | |
| 3 | 40 (48) | 19 (45) | 21 (50) | .39 |
| 4-5 | 17 (20) | 11 (26) | 6 (14) |
| Clinical characteristics . | All patients, N = 84 . | “Low” BMI-1 group, n = 42 . | “High” BMI-1 group, n = 42 . | P* . |
|---|---|---|---|---|
| Median age, y (range) | 36.0 (4.9-59.1) | 36.3 (4.9-59.1) | 33.4 (9.7-55.4) | .91 |
| Patient/donor sex, no. (%) | ||||
| Male/male | 23 (27) | 12 (29) | 11 (26) | |
| Male/female | 25 (30) | 17 (40) | 8 (19) | .76 |
| Female/male | 13 (16) | 6 (14) | 7 (17) | |
| Female/female | 23 (27) | 7 (14) | 16 (38) | |
| Patient/donor CMV serologic status, no. (%) | ||||
| Negative/negative | 21 (25) | 7 (17) | 14 (33) | |
| Negative/positive | 24 (29) | 14 (33) | 10 (24) | .3 |
| Positive/negative | 5 (6) | 2 (5) | 3 (7) | |
| Positive/negative | 34 (40) | 19 (45) | 15 (36) | |
| Allo-SCT era, no. (%) | ||||
| Prior to 1994 | 50 | 25 (59) | 17 (41) | .08 |
| 1994-2002 | 50 | 17 (41) | 25 (59) | |
| Conditioning regimen prior to allo-SCT | ||||
| High-dose chemotherapy alone | 5 (6) | 4 (10) | 1 (2) | |
| Chemotherapy and 10 Gy TBI | 10 (12) | 5 (12) | 5 (12) | .11 |
| Chemotherapy and 12 Gy TBI | 29 (35) | 18 (43) | 11 (26) | |
| Chemotherapy and 13.2 Gy TBI | 40 (47) | 15 (36) | 25 (60) | |
| GVHD prophylaxis regimen, no. (%) | ||||
| Cyclosporine A and methotrexate | 68 (81) | 32 (76) | 36 (86) | .27 |
| T-cell depletion | 16 (19) | 10 (24) | 6 (14) | |
| EBMT-Gratwohl score, no. (%) | ||||
| 1-2 | 27 (32) | 12 (29) | 15 (36) | |
| 3 | 40 (48) | 19 (45) | 21 (50) | .39 |
| 4-5 | 17 (20) | 11 (26) | 6 (14) |
All patients received allo-SCT from an HLA-identical sibling, 81 (96%) received a bone marrow graft, and 3 (4%) received peripheral blood stem cells. None of the patients received antithymocyte globulin for GVHD prophylaxis. The median expression level for BMI-1 was used to segregate the patients into 2 groups (“low,” gene expression less than median; “high,” gene expression greater than median).
CMV indicates cytomegalovirus.
Comparison between the “low” and “high” BMI-1 groups.